MEDILOGIN | Medical Academy

Biologics for the treatment of melanoma

Complementary to the last blog post (“Biologics in dermatology“), which dealt with the use of biotechnologically produced drugs (biologics) for the treatment of psoriasis, we would like to discuss biologics for the therapy of melanoma in this article.

Two approach mechanisms

In the treatment of melanoma, biologics are used in the form of checkpoint inhibitors. There are two approaches:

Melanoma treatment

Firstly, CTLA-4 inhibitors can reduce the anti-proliferative effect on activated T-cells. Secondly, inhibiting the PD-1 signalling pathway (Fig. 1) stimulates the antitumoral immune response, which also increases the number of activated T cells.

This is made possible due to the reduction of apoptosis of regulatory T-cells and the induction of apoptosis of antigen-specific T-cells through the PD-1 signalling pathway.

Table of Contents

Fig. 1: Inhibition of the PD-1 signalling pathway; modified according to 1


Current active agents

The following biologics are currently (as of September 2021) available for the treatment of melanoma:

More information: KV Quota Check on Biologics on the German Doctor Portal DeutschenArztPortal


Rp. Institut /

You can subscribe to the Rp. Praxis-Newsletter here:


  1. Lyons TG und Ku GY. Chin Clin Oncol 2017; 6 (5): 53

Abonniere unseren Newsletter

Erfahre als Erster von Neuigkeiten in der ästhetischen Medizin und profitiere von exklusiven Angeboten sowie Tipps von unseren erfahrenen Dozenten.